Q1 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Supernus Pharmaceuticals Inc (SUPN) reported a 26% increase in total revenues excluding Trokendi XR and Oxtellar XR, driven by strong performance from Qelbree and GOCOVRI.
- Qelbree prescriptions grew by 22% and net sales increased by 44% in the first quarter, with a record high of 75,277 monthly prescriptions in March.
- The launch of ONAPGO, a new growth product for Parkinson's disease, has shown encouraging initial responses from physicians.
- Supernus Pharmaceuticals Inc (SUPN) has a strong balance sheet with $463.6 million in cash, cash equivalents, and marketable securities, providing financial flexibility for potential M&A opportunities.
- The company is advancing its CNS pipeline with plans to initiate a Phase 2b trial for SPN-820 in major depressive disorders, indicating a commitment to R&D and future growth.
- Combined net sales of legacy products Trokendi XR and Oxtellar XR were down 46% in the first quarter, with further erosion expected throughout 2025.
- The company reported a GAAP net loss of $11.8 million for the first quarter of 2025, compared to net earnings in the prior year quarter.
- Operating loss on a GAAP basis increased to $10.3 million, primarily due to higher contingent consideration loss.
- The Medicare Inflation Reduction Act has led to increased mandatory Medicare manufacturer payments, which could impact financial performance despite increased prescriptions.
- Potential import tariffs on products manufactured in Europe or Canada could affect MYOBLOC, XADAGO, or Osmolex ER, introducing uncertainty in cost management.
Good afternoon and welcome to Supernus Pharmaceuticals first-quarter 2025 financial results conference call. (Operator Instructions)
As a reminder, this conference call is being recorded. I would now like to turn the conference over to Peter Vozzo of ICR Westwicke, Investor Relations representative for Supernus Pharmaceuticals. You may begin.
Thank you, Lauren. Good afternoon, everyone, and thank you for joining us today Supernus Pharmaceuticals first-quarter of 2025 financial results conference call. Today, after the close of the market, the company issued a press release announcing these results. On the call with me today is the Chief Executive Officer Jack Khattar and Chief Financial Officer Tim Dec.
This call is being made available via the Investor Relations section of the company's website at ir.supernus.com. During the course of this call, management may make certain forward-looking statements regarding future events and the company's future performance. These forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
